- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for prostate cancer: False promises or true hope?
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 23, Pages 3598-3607
Publisher
Wiley
Online
2016-09-21
DOI
10.1002/cncr.30250
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
- (2016) Cora Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
- (2016) Brian T. Rekoske et al. OncoImmunology
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
- (2015) Michal Podrazil et al. Oncotarget
- PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization
- (2015) B. T. Rekoske et al. Cancer Immunology Research
- Are BiTEs the “missing link” in cancer therapy?
- (2015) Carter M Suryadevara et al. OncoImmunology
- Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors
- (2014) J. Fu et al. CANCER RESEARCH
- Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
- (2014) D. G. McNeel et al. CLINICAL CANCER RESEARCH
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- (2013) M. Dror Michaelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
- (2012) Saskia J. A. M. Santegoets et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
- (2011) Douglas G. McNeel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- (2011) Roberto Pili et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
- (2010) B. Jena et al. BLOOD
- HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase
- (2010) Brian M. Olson et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses
- (2010) Matthew D. Morse et al. HUMAN IMMUNOLOGY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
- (2010) Anders Olsson et al. Molecular Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
- (2010) R. A. Madan et al. ONCOLOGIST
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- (2009) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- Intralesional recombinant α-interferon for localized prostate cancer: a pilot study with follow-up of >10 years
- (2009) Laurel Emerson et al. BJU INTERNATIONAL
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results
- (2009) D. M. Lubaroff et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
- (2009) Per Björk et al. PLOS BIOLOGY
- Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate
- (2008) Robert J. Amato et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started